Clin J Am Soc Nephrol June 2024 PMID 38416033

Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): A Randomized Placebo-Controlled Clinical Trial.

Line A Mortensen, Bente Jespersen, Anne Sophie L Helligsoe, Birgitte Tougaard, Donata Cibulskyte-Ninkovic, Martin Egfjord, Lene Boesby, Niels Marcussen, Kirsten Madsen, Boye L Jensen, Inge Petersen, Claus Bistrup, Helle C Thiesson

Full text PDF Download social card

Mentions

Peak: 24 in May 2024

across 2 sources since Mar 2024

Extended reach

109,181

potential audience

Total likes

231

Video views

1,766

Mentions per month

Mar 2024 – Jul 2024

Where it's discussed

X / Twitter44 posts
YouTube2 videos

AI synopsis

What people are saying

The discussions reveal a cautious interest, highlighting that while spironolactone is deemed safe in this patient group, it does not offer meaningful benefits in preventing kidney decline or fibrosis, as evidenced by phrases like 'no impact', 'nothing clinically relevant', and 'does not affect long-term outcomes'. Words such as 'safe' and 'no benefit' reflect a tone of cautious neutrality and scientific assessment, emphasizing the importance of clinical relevance over safety alone.

AgreementModerate agreement

Most discussions concur that spironolactone appears safe but does not significantly improve long-term kidney outcomes for transplant recipients.

InterestModerate interest

The posts demonstrate moderate curiosity, focusing on the safety profile, short-term effects, and comparing different doses used in the trial.

EngagementModerate engagement

Participants reference specific trial results, such as the lack of impact on kidney function or fibrosis, indicating a moderate level of detailed analysis and engagement.

ImpactModerate impact

Overall, the discussions suggest the research's findings are relevant but are viewed as having limited immediate clinical impact, acknowledging safety but questioning efficacy.

Abstract in brief

The SPIREN trial found that spironolactone is safe for kidney transplant patients, but it temporarily reduces kidney function without affecting its long-term decline or the progression of kidney tissue fibrosis.
Spironolactone treatment resulted in a short-term decrease in measured glomerular filtration rate (GFR) and 24-hour proteinuria, but no significant changes in interstitial fibrosis or long-term kidney health were observed over three years.
Overall, adding spironolactone did not improve kidney function, reduce fibrosis, or enhance transplant survival, indicating that it may not provide long-term benefits in this setting despite some early effects.]

Read the full abstract

All mentions

Mineralocorticoid Antagonists in Advanced Kidney Disease

Explore the evidence behind mineralocorticoid receptor antagonists (MRA) in advanced chronic kidney disease (CKD). Experts discuss trial outcomes, including insights from ALCHEMIST SPIREN and ACHIEVE. Learn from leading…

MARKUS at HOMe · Jul 19, 2024 1,127 views

Hypertension in Kidney Transplant Patients: Pathophysiology and Management

Prof Dr Halimi discusses current concepts on the pathophysiology, diagnosis, and treatment of hypertension in renal transplant recipients, emphasizing guidelines and recent research findings.

MARKUS at HOMe · Jul 4, 2024 639 views

Tomas Rohal

@calvapo · X

RT @drniranjanmr2: Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial) Spironolactone is safe…

Jun 20, 2024 · 1 share · 1,425 followers View post →

Dr Niranjan MR @ NephroByte MD DM DNB

@drniranjanmr2 · X

Jun 20, 2024 · 11 likes · 1 share · 898 followers View post →

Juan Carlos Garcia Aramayo

@jcaramayo · X